Multiple Myeloma Diagnosis and Evaluation

Learn about Multiple Myeloma Diagnosis. Explore bone marrow biopsies, genetic testing (FISH), and PET-CT imaging used at Liv Hospital for precise evaluation.

Diagnosis and Evaluation

Precision Testing for Personalized Care

Receiving a potential diagnosis of multiple myeloma can be a time of intense anxiety and uncertainty. Accurate diagnosis is the cornerstone of effective treatment; it determines not just if you have the condition, but specifically which type and how aggressive it might be.

At Liv Hospital, we utilize a comprehensive, multi-step diagnostic approach. We move beyond simple blood tests to employ advanced genetic profiling and high-resolution imaging. This allows our multidisciplinary team of hematologists and pathologists to construct a detailed "roadmap" of the disease, ensuring that your treatment plan whether it involves novel drug therapies or stem cell transplantation is perfectly tailored to your unique biological profile.

This guide explains the specific tests used to confirm multiple myeloma, what to expect during a bone marrow biopsy, and how doctors determine the stage of the disease.

Why Are Genetic Tests (FISH and Cytogenetics) Important?

Diagnosing multiple myeloma is no longer just about confirming the cancer; it is about understanding its genetic behavior. This is called Risk Stratification.

Once the bone marrow sample is obtained, we perform Fluorescence In Situ Hybridization (FISH) and Cytogenetic Analysis. These advanced tests look for specific chromosomal changes in the myeloma cells, such as:

• Translocations: Parts of chromosomes swapping places (e.g., t(4;14)).
• Deletions: Missing parts of chromosomes (e.g., del(17p)).

Why This Matters: Patients with "High-Risk" genetic markers may require more aggressive initial therapy or a tandem stem cell transplant, while "Standard-Risk" patients may respond excellently to conventional protocols. This personalized genetic insight is vital for long-term success.

How Do Imaging Tests Reveal Bone Damage?

Myeloma cells can weaken bones, causing "lytic lesions" (soft spots) or fractures that might not be immediately painful. Accurate imaging helps us see the extent of the disease throughout the skeleton.

• Low-Dose Whole Body CT: This has largely replaced standard X-rays because it provides a much more detailed 3D view of the bones and can detect smaller lesions.
• MRI (Magnetic Resonance Imaging): An MRI is highly sensitive and is used to detect myeloma in the spine or pelvis, especially if the doctor suspects the cancer is pressing on the spinal cord.
• PET-CT Scan: This combines metabolic and anatomical imaging. It highlights areas of active cancer growth (which light up on the scan) throughout the entire body. It is crucial for determining the stage of the disease and checking how well the treatment is working later on.

How Is Multiple Myeloma Detected via Blood and Urine?

The diagnostic journey often begins with blood work. Unlike solid tumors that form a lump, multiple myeloma is a cancer of the plasma cells in the blood and marrow. Therefore, the chemical signature of the disease is often found circulating in your system.

Key Laboratory Tests:

• Serum Protein Electrophoresis (SPEP): This is the primary screening test. It separates proteins in the blood to find the abnormal "M protein" (monoclonal protein) produced by myeloma cells. A spike in this protein is a strong indicator of the disease.
• Immunofixation Electrophoresis (IFE): This test is more sensitive than SPEP and identifies the exact type of abnormal antibody (e.g., IgG, IgA) being produced.
• Serum Free Light Chain Assay: Sometimes, myeloma cells don't produce a full M protein but only small pieces called "light chains." This test measures these chains to detect myeloma that SPEP might miss.
• Beta-2 Microglobulin (β2M): A high level of this protein indicates a more advanced stage of the disease and helps doctors predict the prognosis.
• Urine Tests (UPEP): Doctors analyze a 24-hour urine sample to check for "Bence Jones proteins," which are light chains that have been filtered by the kidneys.

What Happens During a Bone Marrow Biopsy?

While blood tests provide strong clues, a bone marrow biopsy is the "gold standard" for a definitive diagnosis. We understand that the thought of this procedure can be frightening for many patients. At Liv Hospital, we prioritize your comfort, using local anesthesia and sedation options to minimize discomfort.

The Procedure Steps:

1. Aspiration: A thin needle is used to withdraw a liquid sample of the bone marrow, usually from the back of the hip bone (pelvis).
2. Biopsy: A slightly larger needle removes a small core of solid bone marrow tissue.
3. Pathology Review: Our expert hematopathologists examine the samples under a microscope to calculate the percentage of plasma cells. (In healthy marrow, plasma cells are less than 5%; in multiple myeloma, they are typically more than 10%).

This procedure is quick, typically taking less than 20 minutes, and is performed on an outpatient basis.

Liv Hospital’s Diagnostic Advantage

Time is often a critical factor for international patients. At Liv Hospital, our diagnostic infrastructure is designed for speed and accuracy.

• Rapid Results: Our on-site pathology and genetic labs reduce waiting times significantly, often providing preliminary results within 24-48 hours.
• Tumor Council: Every multiple myeloma case is reviewed by a multidisciplinary board, ensuring that your diagnosis is evaluated by hematologists, radiologists, and pathologists collaboratively.

How Is Multiple Myeloma Staged?

Staging helps the medical team understand how much cancer is in the body and the likely prognosis. Multiple Myeloma is staged using the Revised International Staging System (R-ISS), which combines three factors:

1. Blood markers: Levels of Beta-2 microglobulin and Albumin.
2. Genetics: Presence of high-risk chromosomal abnormalities (from FISH tests).
3. LDH Levels: Lactate Dehydrogenase levels in the blood.

The Stages:

• Stage I: Low levels of beta-2 microglobulin, normal albumin, no high-risk genetics. The outlook is excellent.
• Stage II: Intermediate levels; falling between Stage I and III.
• Stage III: High levels of beta-2 microglobulin, high-risk genetics, or high LDH. This indicates aggressive disease requiring immediate, intensive management.